SYNOPSIS Continuous therapy with synthetic progestogen-oestrogen produces marked atrophy of endometrial glands and massive pseudodecidual stromal transformation. Cyclical therapy produces initially a 'frustrated secretory response' with precocious attempts at secretion in poorly developed glands. Pseudodecidua appears about the 20th day. With later cycles there is progressively greater gland atrophy while pseudodecidua is less marked. A possible inductive role of the glands on the stromal response to progestogens is postulated. The effect of different drugs and dosages is discussed.
The introduction of these drugs is important to the pathologist because they produce endometrial and other uterine changes with which one must be familiar for the interpretation of appearances in endometrial curettings and hysterectomy specimens. The synthetic progestational steroids can be divided into four groups on a chemical basis: Received for publication 17 March 1967. powerful ovulation-inhibitors than group II drugs. They have no inherent oestrogenic activity and do not metabolize to oestrogen. It is difficult to generalize about the effect of cyclic therapy because differences are found, depending on drug dosage, the number of cycles of therapy, and other factors. The following applies to patients taking 5 to 10 mg. norethynodrel or 3 to 5 or even 10 mg. norethisterone acetate.
In the first few cycles glandular proliferation, gauged by size and mitoses, is diminished and then abolished. Subnuclear vacuolation occurs early and is prominent at about nine to 12 days; supranuclear vacuoles may also be found. Subnuclear vacuoles are present in rather small glands, usually distinguishable from the larger more tortuous glands of a normal 17th day endometrium (Fig. 4) . As epithelial vacuolation recedes, luminal secretion appears about the 12th day, reaches a peak about the 14th or 15th day and disappears slowly thereafter. Secretion is scanty and on cursory examination the glands may appear nonsecretory. The glands become smaller later in the cycle (Figs. 5 and 6) but a few tortuous glands may remain. Stromal proliferation is also suppressed but pseudodecidual change usually takes place about the 20th day of the cycle, i.e., after 15 days of treatment, becoming progressively more pronounced and sometimes as conspicuous as that of the normal menstrual (Table I) . Pseudodecidua, often more marked in the superficial endometrium, shows also a tendency to localize around glands and vessels (Fig. 6) . A variable degree of stromal oedema is found at any time of the cycle. With the second to fifth cycles glands tend to remain progressively smaller, attaining a lesser degree of development early in the cycle. Pseudodecidua is less marked; by the fourth or fifth cycle it may be very patchy and inconspicuous. From the sixth to the 60th cycles endometrial glands are usually uniformly small, with inactive epithelium virtually devoid of mitoses, with dense eosinophilic cytoplasm and a sharp luminal edge. Luminal secretion is now minimal or absent but subnuclear vacuolation may still be seen, especially with small doses (Fig. 4) Vascular changes are similar to those seen on continuous therapy. There is partial or complete suppression of development of spiral arterioles, with development of thin-walled sinusoids which sometimes appear ectatic (Fig. 9) . These sinusoids can be mistaken for dilated glands with flattened epithelium. In one patient with Arias-Stella change, an endometrial polyp contains large branched glands and an abundance of muscular arterioles, i.e. looks very different from the remainder of the endometrium.
Two patients with abnormal gynaecological histories merit separate mention. In one, curettage for metrorrhagia showed cystic endometrial hyperplasia. Following Primolut N for two cycles, curettage revealed secretory glands and a pseudodecidual reaction. Curettage in a second patient with metrorrhagia showed focal hyperplasia. After one cycle of Enavid therapy, curettage on the 26th day showed a few secretory glands among a majority of small nonsecretory ones.
RECOVERY PHASE This covers curettings from patients who have discontinued treatment for seven days or more, except for one patient with a gap of only four days. Eleven patients were in the recovery phase, one after continuous therapy for four months, 10 after cyclical therapy for periods varying between two and 48 months. In the patient on continuous treatment curettage revealed, four days after stopping therapy, an early proliferative endometrium with epithelial, but very rare stromal, mitoses. This appears to indicate that partial recovery can take place in only four days. In the 10 patients on cyclical therapy, treatment had been discontinued for between four months and only seven days. Curettage showed normal proliferative or secretory endometrium in all. As examples of the endometrial capacity to recover, two instances are cited. A patient on 2-5 mg. Conovid E for four years as a contraceptive and another treated for almost one year with massive Enavid therapy of up to 80 mg. daily for uncontrollable metrorrhagia both had normal proliferative endometria after stopping treatment. While no abnormalities were seen in these 11 patients, in a patient still on continuous therapy a small,circumscribed stromal nodule of fibroblast-like cells is present.
MYOMETRIUM Of 12 cases undergoing hysterectomy, seven had uterine myomata and, of these, three showed red degeneration. These patients received treatment for periods of nine days, four weeks, and six weeks respectively. The first received only 1 mg. Metrulen M daily for nine days; the last was on continuous therapy for six weeks with Primolut N. In all three cases multiple myomata were present but only one in each case showed red degeneration. In two this affected the largest myoma present (9 cm. and 4 cm.) while in the third, one of the smaller myomata (1 cm.) was affected.
DISCUSSION
CONTINUOUS THERAPY This produces florid pseudodecidual change but with dissociation between glandular and stromal effects. Dockerty, Smith, and Symmonds (1959) drew attention to this change in their case 3. The development of abnormal thinwalled vessels in these endometria is probably respons-Synthetic progestogen-oestrogen therapy and uterine changes ible for the breakthrough bleeding that may occur. In two of our cases uterine bleeding persisted up to the time of hysterectomy or curettage and yet the endometrium was still thick and showed pseudodecidua. This we believe represents bleeding without menstruation.
Since continuous therapy is used in the treatment of endometriosis, it is noteworthy that ectopic endometrium may respond like the normally placed tissue (Lebherz and Fobes, 1961) . This can lead to the pathologist being confronted with a biopsied or resected 'tumour' with very baffling appearances.
CYCLICAL THERAPY Depressed gland proliferation and 'frustrated secretion' epitomize the epithelial changes. Epithelial vacuoles appear precociously but the secretory response is incomplete and luminal secretion diminished. Repressed secretion is probably the result of and proportionate to failure of glandular development. Pseudodecidua appears about the 20th day and may become well developed. With subsequent cycles epithelial vacuolation is slighter, perhaps because gland atrophy is more complete, and pseudodecidual change is less marked. The finding of slight pseudodecidua as early as the seventh day by Ryan, Craig, and Reid (1964) was not confirmed. This variation with the number of cycles was seen also by Rice-Wray, Aranda-Rosell, Maqueo, and Goldzieher, (1963) . The reason for the lessening of the pseudodecidual response is far from clear though one possibility is that development ofendometrial glands plays an inductive role in the response of the stroma to progestogen. This is suggested by a few cases with pseudodecidua around larger glands when there is none around completely atrophic ones. An alternative possibility is that alterations in vascular flow account for the diminished stromal response.
EFFECT OF SIZE OF DOSE Flowers (1964) found no variation between successive cycles using low-dosage therapy. Epithelial vacuolation appeared somewhat later, while there was no pseudodecidual change. Subnuclear vacuolation was consistently present in the second year of therapy, perhaps because this lowdosage therapy caused less gland suppression early in the cycle (Fig. 4) In this context it is believed that progestogen allows endometrial glands to secrete by antagonizing oestrogen, which is a secretion inhibitor (Ober, 1966 (Ober, 1966) . In addition to group differences, there are minor differences between individual drugs. Maqueo, Perez-Vega, Goldzieher, Martinez-Manautou, and Rudel (1963) found that norethynodrel, compared with norethisterone, caused more oedema (Fig. 9) ARIAS-STELLA-LIKE CHANGES These changes were present in two women taking moderate drug doses as contraceptive therapy. It has hitherto been accepted that the Arias-Stella reaction only occurs in the presence of trophoblastic tissue and that it is a sign of pregnancy in uterine and extrauterine sites (Birch and Collins, 1961; Mackles, Wolfe, and Pozner, 1961) . However, Arias-Stella (1955) found that this reaction could be induced by giving oestrogen and progesterone for 18 to 20 days to castrated rats; oestrogen alone failed to produce this effect.
VASCULAR ALTERATIONS Ober drew attention to the importance of vascular changes. Inhibition of development of spiral arterioles is common to all progestogen-oestrogen regimens. Dilated venules are often present, more frequently in therapy with 19-nor-testosterone than with 17a-hydroxyprogesterone derivatives. With less than 2 mg. of any type of drug venule ectasia is rare.
EFFECT ON ABNORMAL ENDOMETRIA Treatment converted two previously hyperplastic endometria into near-normal secretory endometria while a third case of focal endometrial hyperplasia showed, after treatment, focal secretory glands among atrophic ones. It is tempting to think that the 'overprimed' endometrium responds by the development of secretory glands. Should further data confirm this, it would imply that the presence after treatment of full-blown secretory glands probably indicates a preceding hyperplasia.
RECOVERY PHASE Discontinuation of therapy is believed to lead to a return to a normal endometrium and this is true of our 11 cases. Charles (1964) 
